Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the “Notification Letter”)
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the “Notification Letter”)
FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the evaluation of lung ventilation
First healthy volunteers dosed on schedule
SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
Clinical Study results on the influence
Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma
Midatech Pharma (MTPH), an R&D biotechnology company, said that Rolf Stahel, Chairman and non-executive director, intends to retire after the company’s AGM on 20 June 2022.
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
Feedback receives funding from Amazon Web Services in support of its cloud-based tuberculosis screening programme for rural communities in India
The medical community is now closer than ever to finding treatments for Alzheimer’s disease.
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data